{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:44:51Z","timestamp":1768902291522,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,5]]},"DOI":"10.7759\/cureus.53644","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T20:48:21Z","timestamp":1707166101000},"source":"Crossref","is-referenced-by-count":1,"title":["Compare the Efficacy and Safety of Deferoxamine, Deferasirox, and Deferiprone in Patients With Sickle Cell Disease or Transfusion-Dependent Anemia: A Network Meta-Analysis of Randomized Control Trials"],"prefix":"10.7759","author":[{"given":"Divine Besong","family":"Arrey Agbor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhimanyu","family":"Karumanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santoshini","family":"Adivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajeeh","family":"Ur Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thin M","family":"Soe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelum","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201111-2082CI","article-title":"Pulmonary complications of sickle cell disease","volume":"185","author":"Miller AC","year":"2012","unstructured":"Miller AC, Gladwin MT. Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med. 2012, 185:1154-65. 10.1164\/rccm.201111-2082CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13791","article-title":"Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial","volume":"172","author":"Wood JC","year":"2016","unstructured":"Wood JC, Cohen AR, Pressel SL, et al.. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. Br J Haematol. 2016, 172:122-30. 10.1111\/bjh.13791","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13023","article-title":"Sickle cell disease: reducing the global disease burden","volume":"41 Suppl 1","author":"Mburu J","year":"2019","unstructured":"Mburu J, Odame I. Sickle cell disease: reducing the global disease burden. Int J Lab Hematol. 2019, 41 Suppl 1:82-8. 10.1111\/ijlh.13023","journal-title":"Int J Lab Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.625","article-title":"Sickle cell disease: when and how to transfuse","volume":"2016","author":"Howard J","year":"2016","unstructured":"Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016, 2016:625-31. 10.1182\/asheducation-2016.1.625","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20809","article-title":"Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload","volume":"82","author":"Fung EB","year":"2007","unstructured":"Fung EB, Harmatz P, Milet M, et al.. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol. 2007, 82:255-65. 10.1002\/ajh.20809","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061456","article-title":"Iron and chelation in biochemistry and medicine: new approaches to controlling iron metabolism and treating related diseases","volume":"9","author":"Kontoghiorghes GJ","year":"2020","unstructured":"Kontoghiorghes GJ, Kontoghiorghe CN. Iron and chelation in biochemistry and medicine: new approaches to controlling iron metabolism and treating related diseases. Cells. 2020, 9:10.3390\/cells9061456","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-370098","article-title":"How I treat transfusional iron overload","volume":"120","author":"Hoffbrand AV","year":"2012","unstructured":"Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012, 120:3657-69. 10.1182\/blood-2012-05-370098","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012349.pub2","article-title":"Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia","volume":"5","author":"Fortin PM","year":"2018","unstructured":"Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database Syst Rev. 2018, 5:CD012349. 10.1002\/14651858.CD012349.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2014.04.004","article-title":"Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial","volume":"53","author":"Calvaruso G","year":"2014","unstructured":"Calvaruso G, Vitrano A, Di Maggio R, et al.. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells Mol Dis. 2014, 53:265-71. 10.1016\/j.bcmd.2014.04.004","journal-title":"Blood Cells Mol Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1657667","article-title":"The challenges of handling deferasirox in sickle cell disease patients older than 40 years","volume":"24","author":"Ribeiro LB","year":"2019","unstructured":"Ribeiro LB, Soares EA, Costa FF, Gilli SC, Olalla Saad ST, Benites BD. The challenges of handling deferasirox in sickle cell disease patients older than 40 years. Hematology. 2019, 24:596-600. 10.1080\/16078454.2019.1657667","journal-title":"Hematology"},{"key":"ref11","unstructured":"Ferriprox. Summary of product characteristics. (2021). Accessed. January 12, 2024: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ferriprox."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.10.015","article-title":"Deferasirox for transfusion-related iron overload: a clinical review","volume":"29","author":"Lindsey WT","year":"2007","unstructured":"Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther. 2007, 29:2154-66. 10.1016\/j.clinthera.2007.10.015","journal-title":"Clin Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113967","article-title":"Redox interactions of vitamin C and iron: Inhibition of the pro-oxidant activity by deferiprone","volume":"21","author":"Timoshnikov VA","year":"2020","unstructured":"Timoshnikov VA, Kobzeva TV, Polyakov NE, Kontoghiorghes GJ. Redox interactions of vitamin C and iron: Inhibition of the pro-oxidant activity by deferiprone. Int J Mol Sci. 2020, 21:10.3390\/ijms21113967","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24966","article-title":"Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: a randomized controlled trial","volume":"93","author":"Elalfy MS","year":"2018","unstructured":"Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: a randomized controlled trial. Am J Hematol. 2018, 93:262-8. 10.1002\/ajh.24966","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004938","article-title":"Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study","volume":"6","author":"Kwiatkowski JL","year":"2022","unstructured":"Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al.. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022, 6:1243-54. 10.1182\/bloodadvances.2021004938","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP- 2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio A","year":"2020","unstructured":"Maggio A, Kattamis A, Felisi M, et al.. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP- 2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol. 2020, 7:469-478. 10.1016\/S2352-3026(20)30100-9","journal-title":"Lancet Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23569","article-title":"Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea","volume":"88","author":"Vichinsky E","year":"2013","unstructured":"Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol. 2013, 88:1068-73. 10.1002\/ajh.23569","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","author":"Vichinsky E","year":"2007","unstructured":"Vichinsky E, Onyekwere O, Porter J, et al.. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007, 136:501-8. 10.1111\/j.1365-2141.2006.06455.x","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1800219","article-title":"The role of deferiprone in iron chelation","volume":"379","author":"Hider RC","year":"2018","unstructured":"Hider RC, Hoffbrand AV. The role of deferiprone in iron chelation. N Engl J Med. 2018, 379:2140-50. 10.1056\/NEJMra1800219","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03630269.2022.2072320","article-title":"Adherence to iron chelation therapy among adults with thalassemia: a systematic review","volume":"46","author":"Locke M","year":"2022","unstructured":"Locke M, Reddy PS, Badawy SM. Adherence to iron chelation therapy among adults with thalassemia: a systematic review. Hemoglobin. 2022, 46:201-13. 10.1080\/03630269.2022.2072320","journal-title":"Hemoglobin"},{"key":"ref21","unstructured":"FerriproxVR (deferiprone) oral solution, for oral use. (2021). Accessed. January 12, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208030lbl.pdf."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload","volume":"102","author":"Hoffbrand AV","year":"2003","unstructured":"Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003, 102:17-24. 10.1182\/blood-2002-06-1867","journal-title":"Blood"},{"key":"ref23","unstructured":"FerriproxVR (deferiprone) tablets. (2021). Accessed. January 12, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021825lbl.pdf."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44646","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis","volume":"7","author":"Srivastava K","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013, 7:419-34. 10.2147\/PPA.S44646","journal-title":"Patient Prefer Adherence"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ec0f13","article-title":"The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload","volume":"32","author":"ElAlfy MS","year":"2010","unstructured":"ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010, 32:601-5. 10.1097\/MPH.0b013e3181ec0f13","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/121762","article-title":"Chelation therapy with oral solution of deferiprone in transfusional iron-overloaded children with hemoglobinopathies","volume":"2013","author":"Makis A","year":"2013","unstructured":"Makis A, Chaliasos N, Alfantaki S, Karagouni P, Siamopoulou A. Chelation therapy with oral solution of deferiprone in transfusional iron-overloaded children with hemoglobinopathies. Anemia. 2013, 2013:121762. 10.1155\/2013\/121762","journal-title":"Anemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/227069-compare-the-efficacy-and-safety-of-deferoxamine-deferasirox-and-deferiprone-in-patients-with-sickle-cell-disease-or-transfusion-dependent-anemia-a-network-meta-analysis-of-randomized-control-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:17:10Z","timestamp":1707509830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/227069-compare-the-efficacy-and-safety-of-deferoxamine-deferasirox-and-deferiprone-in-patients-with-sickle-cell-disease-or-transfusion-dependent-anemia-a-network-meta-analysis-of-randomized-control-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.53644","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}